莫西沙星对老年社区获得性肺炎患者抗感染疗效及肺功能的影响

Effect of moxifloxacin on anti infective efficacy and pulmonary function in elderly patients with community acquired pneumonia

目的探讨莫西沙星在老年社区获得性肺炎(CAP)患者抗感染疗效及肺功能的影响。方法选取2014年1月-2016年12月医院收治的老年CAP患者126例,分为对照组和试验组,各63例。对照组患者采用左氧氟沙星序贯治疗,试验组患者采用莫西沙星序贯治疗,观察患者治疗前后肺功能水平;采用酶联免疫吸附试验测定两组患者治疗前后C-反应蛋白(CRP)、降钙素原(PCT)、骨膜蛋白及可溶性髓系细胞表达触发蛋白-1(sTREM-1)水平,比较两组患者临床疗效及肺功能[肺1s用力呼气量(FEV1)、最大呼吸量(FVC)及FEV1/FVC、FEV1占预计值百分比(FEV1)及最大呼气流量(PEF)]。结果治疗后,试验组患者FEV1、FEV1占预计值百分比、PEF及FEV1/FVC分别为(1.99±0.62)L、(63.25±6.41)%、(59.22±4.61)%、(65.36±6.27)L/min均高于对照组患者;治疗后14d试验组患者CRP、PCT、骨膜蛋白、sTREM-1分别为(3.21±0.43)mg/L、(0.11±0.03)μg/ml、(210.12±43.26)μg/L、(41.24±5.46)ng/ml均低于对照组患者(P<0.001);两组患者治疗后14d并发症发生率差异无统计学意义。两组治疗14d后,试验组疗效优于对照组(P<0.05)。结论将莫西沙星序贯治疗用于老年CAP抗感染中效果理想,有助于改善患者肺功能,降低炎症因子水平。

OBJECTIVE To investigate the efficacy of moxifloxacin in the treatment of community-acquired pneumonia（CAP）in elderly patients and its effect on pulmonary function.METHODS A total of 126 cases of elderly CAP patients treated in the hospital from Jan.2014 to Dec.2016 were selected,and were randomly divided into control group（n=63）and experimental group（n=63）.Patients in control group were treated with levofloxacin sequential therapy,and in experimental group were treated with moxifloxacin sequential therapy.Lung function levels were observed in the two groups before and after treatment.The C-reactive protein（CRP）,procalcitonin（PCT）,periosteum protein and soluble triggering receptor expressed on myeloid cells-1（sTREM-1）levels of the two groups before and after treatment were determined by enzyme-linked immunosorbent assay,and the clinical curative effect and lung function（pulmonary 1 sforced expiratory volume（FEV1）,FEV1 percentage of predicted value,and the maximum expiratory flow（PEF））between the two groups were compared.RESULTS After treatment,the FEV1,FEV1 percentage of predicted value,PEF and FEV1/FVC levels in experimental group were（1.99±0.62）L,（63.25±6.41）%,（59.22±4.61）% and（65.36±6.27）L/min,which were higher than those in control group（P〈0.05）.After 14 dof treatment,the CRP,PCT,periosteum protein and sTREM-1 levels in experimental group were（3.21±0.43）mg/L,（0.11±0.03）μg/ml,（210.12±43.26）μg/L and（41.24±5.46）ng/ml,which were lower than those in control group（P〈0.001）.There was no significant difference in the incidence of complications after 4 dof treatment between the two groups.After 14 dof treatment,the efficiency in experimental group was better than that in control group（P〈0.05）.CONCLUSION Moxifloxacin sequential therapy has good efficiency in the treatment of elderly patients with community-acquired pneumonia,which helps to improve pulmonary function,and decrease the levels of inflammatory factors.